AKUS

Akouos, Inc. [AKUS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

AKUS Stock Summary

In the News

10:46 29 Mar 2024 AKUS

Why Is Akouos (AKUS) Stock Up 85% Today?

There's notable merger news today as pharmaceutical giant Eli Lilly (NYSE: LLY ) entered into a definitive agreement to acquire Akouos (NASDAQ: AKUS ). Clearly, Eli Lilly is looking to expand further into gene therapies.

09:37 29 Mar 2024 AKUS

Why Akouos Stock Is on Fire Today

A buyout agreement is lighting a fire underneath the biotech's shares today.

07:05 29 Mar 2024 AKUS

Eli Lilly to buy genetic medicine developer Akouos for $487 million

Drugmaker Eli Lilly and Co will acquire genetic medicine developer Akouos Inc in a cash deal worth about $487 million.

07:01 29 Mar 2024 AKUS

Eli Lilly to acquire Akouos for up to about $610 million and develop gene therapies for hearing loss

Eli Lilly and Co. LLY, +0.41% said Tuesday it has entered an agreement to acquire Akouos Inc. AKUS, -5.14% , a company developing a portfolio of viral gene therapies for the treatment of inner ear conditions including hearing loss, for up to $610 million in cash. Under the terms of the deal, Akouos shareholders will receive $12.50 a share in cash, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $3.00 in cash, for a total consideration of up to $15.50 per share in cash without interest, or an aggregate of $610 million.

01:32 29 Mar 2024 AKUS

Akouos, Inc. (AKUS) Upgraded to Strong Buy: Here's Why

Akouos, Inc. (AKUS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

01:33 29 Mar 2024 AKUS

Akouos, Inc. (AKUS) Upgraded to Buy: Here's Why

Akouos, Inc. (AKUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

07:00 29 Mar 2024 AKUS

Akouos to Present at Bank of America 2022 Healthcare Conference

BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a presentation at the Bank of America 2022 Healthcare Conference on Tuesday, May 10 at 10:00 a.m. PDT in Las Vegas, Nevada.

07:00 29 Mar 2024 AKUS

Akouos to Participate in Upcoming March Virtual Investor Conferences

BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer will participate in two upcoming virtual investor conferences in March:

07:00 29 Mar 2024 AKUS

Akouos to Present at the Association for Research in Otolaryngology 45th Annual Mid-Winter Meeting

BOSTON, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that new nonclinical data will be presented at the Association for Research in Otolaryngology (ARO) 45th Annual Mid-Winter Meeting, which is being held in San Jose, California from February 5 to 9, 2022.

07:00 29 Mar 2024 AKUS

Akouos to Present at Jefferies Gene Therapy/Editing Summit

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a presentation at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27 at 9:30 a.m. EDT.

AKUS Financial details

Company Rating
Neutral
Market Cap
0
Income
-93.37M
Revenue
0
Book val./share
4.9
Cash/share
4.59
Dividend
-
Dividend %
-
Employees
103
Optionable
No
Shortable
Yes
Earnings
15 Nov 2022
P/E
-7.17
Forward P/E
-
PEG
15.28
P/S
-
P/B
2.71
P/C
-
P/FCF
-
Quick Ratio
16.79
Current Ratio
17.3
Debt / Equity
0.2
LT Debt / Equity
0.19
-
-
EPS (TTM)
-2.64
EPS next Y
-
EPS next Q
-
EPS this Y
78.34%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-5.17%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.04%
Inst Trans
0%
ROA
-30%
ROE
-35%
ROC
-0.31%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
36.95M
Shs Float
19.35M
-
-
-
-
Target Price
13
52W Range
2.315-13.6
52W High
-
52W Low
-
RSI
-
Rel Volume
2.47
Avg Volume
725.97K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-0.561325
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

AKUS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2018-12-312019-12-312020-12-31 2021-12-31
2.02K2.02K2.02K2.02K
Revenue per share
0000
Net income per share
-0.93-4-2.77-4.94
Operating cash flow per share
-1.05-3.03-2.32-3.63
Free cash flow per share
-1.13-3.57-2.58-4.15
Cash per share
3.583.917.5513.24
Book value per share
-1.12-5.117.713.31
Tangible book value per share
-1.12-5.117.713.31
Share holders equity per share
-1.12-5.117.713.31
Interest debt per share
00.10.751.65
Market cap
141.56M141.56M348.03M149.18M
Enterprise value
118.54M130.27M292.24M56.25M
P/E ratio
-23.54-5.5-7.16-1.72
Price to sales ratio
0000
POCF ratio
-21.02-7.26-8.54-2.34
PFCF ratio
-19.48-6.17-7.68-2.05
P/B Ratio
-19.58-4.321.120.64
PTB ratio
-19.58-4.321.120.64
EV to sales
0000
Enterprise value over EBITDA
-19.9-5.2-6.29-0.68
EV to operating cash flow
-17.6-6.68-7.17-0.88
EV to free cash flow
-16.31-5.68-6.45-0.77
Earnings yield
-0.04-0.18-0.14-0.58
Free cash flow yield
-0.05-0.16-0.13-0.49
Debt to equity
0-0.020.040.12
Debt to assets
00.010.040.1
Net debt to EBITDA
3.860.451.21.12
Current ratio
4.734.429.0114.06
Interest coverage
0000
Income quality
1.120.760.840.74
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0000
Research and developement to revenue
0000
Intangibles to total assets
0000
Capex to operating cash flow
0.080.180.110.14
Capex to revenue
0000
Capex to depreciation
-9.67-4.94-2.08-2.41
Stock based compensation to revenue
0000
Graham number
4.8621.4233.2138.46
ROIC
1.271.21-0.15-0.3
Return on tangible assets
-0.23-0.57-0.15-0.31
Graham Net
-1.55-8.2216.2510.67
Working capital
18.41M20.2M299.93M219.36M
Tangible asset value
-7.23M-32.8M310.61M233.65M
Net current asset value
-9.67M-51.82M287.9M191.06M
Invested capital
0-0.020.040.12
Average receivables
0000
Average payables
0383K617K1.09M
Average inventory
0000
Days sales outstanding
0000
Days payables outstanding
0000
Days of inventory on hand
0000
Receivables turnover
0000
Payables turnover
0000
Inventory turnover
0000
ROE
0.830.78-0.16-0.37
Capex per share
-0.08-0.53-0.26-0.51

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.67-0.72-0.79-0.58-0.55
Operating cash flow per share
-0.57-0.46-0.58-0.47-0.57
Free cash flow per share
-0.63-0.49-0.66-0.65-0.64
Cash per share
7.256.746.065.384.59
Book value per share
7.446.786.055.524.9
Tangible book value per share
7.446.786.055.524.9
Share holders equity per share
7.446.786.055.524.9
Interest debt per share
0.830.840.850.910.97
Market cap
399.81M292.96M164.01M168.08M249.48M
Enterprise value
313.94M200.03M138.76M127.24M209.44M
P/E ratio
-4.36-2.94-1.51-2.02-3.06
Price to sales ratio
00000
POCF ratio
-20.21-18.38-8.18-9.9-11.82
PFCF ratio
-18.51-17.39-7.18-7.24-10.53
P/B Ratio
1.561.250.780.851.38
PTB ratio
1.561.250.780.851.38
EV to sales
00000
Enterprise value over EBITDA
-14.44-8.36-5.38-6.55-11.45
EV to operating cash flow
-15.87-12.55-6.92-7.5-9.93
EV to free cash flow
-14.54-11.88-6.07-5.48-8.84
Earnings yield
-0.06-0.09-0.17-0.12-0.08
Free cash flow yield
-0.05-0.06-0.14-0.14-0.1
Debt to equity
0.110.120.140.170.2
Debt to assets
0.10.10.110.130.16
Net debt to EBITDA
3.953.890.982.12.19
Current ratio
19.414.0611.3913.3617.3
Interest coverage
00-103.990-37.01
Income quality
0.860.640.740.811.06
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.090.060.140.370.12
Capex to revenue
00000
Capex to depreciation
-1.56-0.88-3.03-4.44-2.54
Stock based compensation to revenue
00000
Graham number
10.5510.5110.368.57.8
ROIC
-0.07-0.09-0.1-0.08-0.08
Return on tangible assets
-0.08-0.09-0.11-0.09-0.09
Graham Net
6.055.444.74.083.38
Working capital
241.39M219.36M192.89M180.33M164.41M
Tangible asset value
256.22M233.65M208.98M197.95M180.84M
Net current asset value
213.27M191.06M164.48M148.33M129.82M
Invested capital
0.110.120.140.170.2
Average receivables
70.22M0000
Average payables
1.07M1.17M1.31M1.01M620.5K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.09-0.11-0.13-0.11-0.11
Capex per share
-0.05-0.03-0.08-0.17-0.07

AKUS Frequently Asked Questions

What is Akouos, Inc. stock symbol ?

Akouos, Inc. is a US stock , located in Boston of Ma and trading under the symbol AKUS

Is Akouos, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $13. The lowest prediction is $13 and the highest is $13

What is AKUS stock prediction ?

What is Akouos, Inc. stock quote today ?

Akouos, Inc. stock price is $- today.

Is Akouos, Inc. stock public?

Yes, Akouos, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Similar Market Cap